244 related articles for article (PubMed ID: 14534739)
1. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
Dahse R; Gärtner D; Werner W; Schubert J; Junker K
Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
[TBL] [Abstract][Full Text] [Related]
2. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
[TBL] [Abstract][Full Text] [Related]
6. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
7. Role of chromosome 9 in human bladder cancer.
Miyao N; Tsai YC; Lerner SP; Olumi AF; Spruck CH; Gonzalez-Zulueta M; Nichols PW; Skinner DG; Jones PA
Cancer Res; 1993 Sep; 53(17):4066-70. PubMed ID: 8358736
[TBL] [Abstract][Full Text] [Related]
8. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
9. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.
Chern HD; Becich MJ; Persad RA; Romkes M; Smith P; Collins C; Li YH; Branch RA
J Urol; 1996 Nov; 156(5):1846-9. PubMed ID: 8863629
[TBL] [Abstract][Full Text] [Related]
10. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
11. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
12. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract.
Hafner C; Knuechel R; Zanardo L; Dietmaier W; Blaszyk H; Cheville J; Hofstaedter F; Hartmann A
Oncogene; 2001 Aug; 20(35):4910-5. PubMed ID: 11521204
[TBL] [Abstract][Full Text] [Related]
13. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns.
Miyake H; Hara I; Kamidono S; Eto H
J Urol; 2004 Sep; 172(3):1127-9. PubMed ID: 15311055
[TBL] [Abstract][Full Text] [Related]
14. [p53 mutation in phenacetin-induced urothelial carcinomas].
Petersen I; Ohgaki H; Ludeke BI; Kleihues P
Verh Dtsch Ges Pathol; 1993; 77():252-5. PubMed ID: 7511292
[TBL] [Abstract][Full Text] [Related]
15. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
16. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer.
Trkova M; Babjuk M; Duskova J; Benesova-Minarikova L; Soukup V; Mares J; Minarik M; Sedlacek Z
Cancer Lett; 2006 Oct; 242(1):68-76. PubMed ID: 16343743
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines.
Yasunaga Y; Nakanishi H; Naka N; Miki T; Tsujimura T; Itatani H; Okuyama A; Aozasa K
Lab Invest; 1997 Dec; 77(6):677-84. PubMed ID: 9426406
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study.
Dalbagni G; Ren ZP; Herr H; Cordon-Cardo C; Reuter V
Clin Cancer Res; 2001 Sep; 7(9):2797-801. PubMed ID: 11555595
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations in urinary bladder cancer.
Berggren P; Steineck G; Adolfsson J; Hansson J; Jansson O; Larsson P; Sandstedt B; Wijkström H; Hemminki K
Br J Cancer; 2001 Jun; 84(11):1505-11. PubMed ID: 11384101
[TBL] [Abstract][Full Text] [Related]
20. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.
Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
Clin Cancer Res; 1996 Oct; 2(10):1795-800. PubMed ID: 9816132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
